Provided herein are compositions and methods related to the treatment of an autoimmune disease in a subject.

Provided herein are compositions and methods related to the treatment of an autoimmune disease in a subject.

Provided herein are methods comprising autologous cytotoxic T cells expressing a T cell receptor that specifically binds to an Epstein Barr virus (EBV) or expressing CD107a, TNF, IFN-gamma or IL-2 for the treatment of multiple sclerosis in a subject or selecting a subject for adoptive immunotherapy.

Provided herein are methods comprising autologous cytotoxic T cells expressing a T cell receptor that specifically binds to an Epstein Barr virus (EBV) or expressing CD107a, TNF, IFN-gamma or IL-2 for the treatment of multiple sclerosis in a subject or selecting a subject for adoptive immunotherapy.

The disclosure provides recombinant polypeptides that specifically bind to an envelope epitope of HERV-K HML-2, wherein such engineered polypeptides may be single-domain antibodies or immunoglobulin variable domains. The disclosure also provides CAR comprising such recombinant polypeptides. The disclosure further provides nucleic acid molecules that encode such recombinant polypeptides or CARs, and methods of making such recombinant polypeptides or CARs. The disclosure further provides pharmaceutical compositions that comprise such recombinant polypeptides or CARs, and methods of treatment using such recombinant polypeptides or CARs.

The disclosure provides recombinant polypeptides that specifically bind to an envelope epitope of HERV-K HML-2, wherein such engineered polypeptides may be single-domain antibodies or immunoglobulin variable domains. The disclosure also provides CAR comprising such recombinant polypeptides. The disclosure further provides nucleic acid molecules that encode such recombinant polypeptides or CARs, and methods of making such recombinant polypeptides or CARs. The disclosure further provides pharmaceutical compositions that comprise such recombinant polypeptides or CARs, and methods of treatment using such recombinant polypeptides or CARs.

Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic agent. In certain instances the immunotherapeutic is an NK cell or a chimeric antigen receptor NK cell.

Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic agent. In certain instances the immunotherapeutic is an NK cell or a chimeric antigen receptor NK cell.

Epstein-Barr virus (EBV) antigen composites and a dendritic cell (DC)-based vaccine, and a use thereof in preparation of a drug for controlling an EBV-associated infectious disease are provided. Patient-derived DCs are stimulated in vitro, loaded with lysates of various types of EBV-infected cells with strong immunogenicity for EBV-associated infectious diseases, and induced into mature dendritic cells (mDCs) by various cytokines and specific agonists, so as to obtain a complete DC-based vaccine with corresponding antigens. The DC-based vaccine can be injected back into the patient to activate the immune system to produce cytotoxic T cells, thereby killing EBV-infected cells, exerting an immunological effect, and improving a life quality of the patient. In addition, the DC-based vaccine can be prepared in about one week with a low cost, is safe, and shows no obvious side effects.

Epstein-Barr virus (EBV) antigen composites and a dendritic cell (DC)-based vaccine, and a use thereof in preparation of a drug for controlling an EBV-associated infectious disease are provided. Patient-derived DCs are stimulated in vitro, loaded with lysates of various types of EBV-infected cells with strong immunogenicity for EBV-associated infectious diseases, and induced into mature dendritic cells (mDCs) by various cytokines and specific agonists, so as to obtain a complete DC-based vaccine with corresponding antigens. The DC-based vaccine can be injected back into the patient to activate the immune system to produce cytotoxic T cells, thereby killing EBV-infected cells, exerting an immunological effect, and improving a life quality of the patient. In addition, the DC-based vaccine can be prepared in about one week with a low cost, is safe, and shows no obvious side effects.